Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial

OBJECTIVE: Previous reports of the RAPID-axSpA trial (NCT01087762) described the efficacy and safety of certolizumab pegol (CZP) over 24 weeks in patients with axial spondyloarthritis (SpA), including ankylosing spondylitis (AS) and nonradiographic axial SpA. We report efficacy and safety data up to...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Arthritis Rheumatol
Asıl Yazarlar: Sieper, J, Landewé, R, Rudwaleit, M, van der Heijde, D, Dougados, M, Mease, P J, Braun, J, Deodhar, A, Kivitz, A, Walsh, J, Hoepken, B, Nurminen, T, Maksymowych, W P
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BlackWell Publishing Ltd 2015
Konular:
Spondyloarthritis
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4365732/
https://ncbi.nlm.nih.gov/pubmed/25470228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.38973
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller